Bedrocan: How a Dutch Greenhouse Made Cannabis a Medicine

If Israeli laboratories worked out what cannabis is — the molecules and the receptors they act on — a Dutch greenhouse worked out how to make it a medicine: standardised, reproducible, and trusted by regulators. That company is Bedrocan, and its decades-long project to turn a famously variable plant into a consistent pharmaceutical raw material is a large part of why a credible medical-cannabis industry exists at all, in Israel as much as in Europe.

This guide is general information, not medical advice. Cannabis is not an established treatment for most conditions; consult a qualified physician.

From chicory to cannabis

Bedrocan did not begin as a cannabis company. It was founded in the Netherlands in 1984 by Tjalling Erkelens and his brother-in-law Freerk Bruining as a family greenhouse business in the country's great horticultural tradition, cultivating chicory, herbs and pot plants in the north of the Netherlands (Newsweed). Cannabis first entered the operation in 1992, and through the 1990s the founders pivoted toward a single, unusual ambition: to apply the most advanced methods of precision agriculture to growing standardised cannabis.

That word — standardised — is the whole story. The obstacle to cannabis ever being treated as a medicine was that no two plants, and no two harvests, were alike. A doctor cannot prescribe a substance whose potency swings unpredictably from batch to batch. Erkelens spent more than two decades solving exactly that problem.

The breakthrough: a plant that is always the same

Bedrocan's core innovation is genetic and procedural consistency. Each of its varieties is grown from genetically identical plants under tightly controlled indoor conditions, so that every batch delivers the same cannabinoid content within a narrow band (Bedrocan). The result is cannabis that behaves like a pharmaceutical ingredient: a patient receives the same product, at the same strength, every time — the prerequisite for any serious clinical use or research.

This is the quiet revolution behind modern medical cannabis. The science of what cannabinoids do was largely Israeli — Raphael Mechoulam's isolation of THC and CBD and discovery of the endocannabinoid system. But that science is only clinically useful if the raw material is reproducible. Bedrocan supplied the missing half: a manufacturing discipline rigorous enough to turn Mechoulam's molecules into something a regulator would license.

The Dutch government model

Bedrocan's standardisation was matched by an institutional innovation. The Netherlands was the first country in Europe to build a state medical-cannabis system with domestic production, established in 2003 and run through the government's Office of Medicinal Cannabis (OMC), part of the Ministry of Health (Bedrocan). The arrangement is distinctive: although the product carries the Bedrocan name, the OMC is the official producer in legal terms. Bedrocan cultivates and manufactures under contract as the sole licensed grower; the government takes possession of the finished cannabis and handles distribution to pharmacies and export on behalf of the state.

That structure made the Netherlands the world's reference supplier of standardised medical cannabis for years. The OMC authorises a small set of named varieties — Bedrocan, Bedrobinol, Bediol, Bedica and Bedrolite — at defined THC and CBD ratios, dispensed by prescription and shipped abroad under government authorisation. Among the markets Dutch flower has reached is Israel itself.

World's first GMP-certified cannabis

The pioneering role became official in 2017, when Bedrocan became the first company in the world to obtain EU-GMP certification for the production of medicinal cannabis (Bedrocan). Good Manufacturing Practice is the standard that governs how real pharmaceuticals are made, and earning it for a cannabis product proved a point many had doubted: that flower could be produced as a standardised active pharmaceutical ingredient, not merely an agricultural commodity.

This is the direct link to Israel. When Israel built its own quality framework — the IMC-GAP and IMC-GMP standards — it modelled them on EU-GMP and the European Pharmacopoeia, the very framework Bedrocan had been first to satisfy. The Dutch demonstrated that pharmaceutical-grade cannabis was achievable; Israel and others then wrote that demonstration into national regulation. The template — standardised genetics, controlled cultivation, GMP manufacturing, prescription dispensing — is now the global default for any country that wants its medical cannabis taken seriously.

The science of standardisation: Arno Hazekamp

Standardisation was not only an agricultural feat — it was a scientific one, and its central figure at Bedrocan was the biochemist Arno Hazekamp, who became the company's head of research in 2011 (Fundación CANNA). His work analysing Bedrocan's plants — learning to identify and isolate every cannabinoid and, crucially, the terpenes that shape a variety's character — turned cultivation into measurable chemistry. Hazekamp and colleagues helped popularise the term "chemovar" (chemical variety) for classifying cannabis by its full cannabinoid-and-terpenoid fingerprint rather than loose "strain" names, explicitly for "drug standardization purposes." Across more than 30 published papers, this is the analytical backbone that lets a producer prove a batch is what the label says — the difference between a herb and a medicine.

The ultimate proof: a real cannabis placebo

Standardisation reaches its logical endpoint in one of Bedrocan's most quietly remarkable products: a genuine cannabis placebo. Rigorous medicine depends on double-blind, placebo-controlled trials, but cannabis is almost impossible to blind — patients can tell real flower from a dummy by smell and taste alone. Bedrocan's answer was to take its standardised material, strip the cannabinoids out to less than 0.2% of dry weight, and then restore the variety's exact terpene profile in a later manufacturing step (Bedrocan). The result looks, smells and tastes like the active product but contains no active ingredient — so a trial subject genuinely cannot tell which they received.

This is only possible because the underlying material is standardised: you can only build a convincing placebo of a product whose chemistry you can reproduce precisely. By making properly blinded cannabis trials feasible, the placebo directly serves the kind of rigorous clinical research Israel is well placed to run — closing the loop between Dutch standardisation and the evidence base the whole field still needs.

Why standardisation lets a device be certified

Here is the payoff that makes standardisation matter beyond the dispensary: you cannot certify a delivery device against a raw material that changes batch to batch. A medical device must demonstrate that it delivers a defined dose, reproducibly — which is impossible if the input is unpredictable. Standardised cannabis is what makes that validation feasible, and the clearest proof is the devices built on Bedrocan material.

The Storz & Bickel Volcano vaporizer — and its successor the Mighty Medic, an approved medical device in the EU, Canada and Israel — was evaluated for pulmonary THC delivery in a foundational 2006 study that Hazekamp co-authored, using Bedrocan's standardised flos (Bedrocan / Hazekamp study). The vaporizer could only be characterised as a reliable, dose-dependent delivery system because the cannabis feeding it was consistent.

The same logic runs straight back to Israel. The Israeli company Syqe Medical built the SyqeAir — the world's only metered-dose cannabis inhaler — around cartridges holding 60 uniform doses of pharmaceutical-grade, standardised Bedrocan flower (Syqe). That precision is what earned it CE and Health Canada clearance and clinical validation (PMC), an Israeli Ministry of Defence contract to treat veterans, and ultimately a Philip Morris acquisition deal valued at up to $650 million. A metered-dose inhaler is only possible on top of a standardised raw material — Israeli device innovation resting directly on the Dutch standardisation that made it thinkable.

A pioneer in transition

After two decades as the Dutch government's sole supplier, Bedrocan is now navigating a shift in the Netherlands toward a new medicinal-cannabis framework, as the long-standing single-supplier model evolves (Bedrocan). The change is a sign of how far the field has matured: what was once a one-company experiment is now a competitive international industry — one that includes a substantial Israeli export sector built on the same pharmaceutical logic Bedrocan established.

Has Israel caught up? Not entirely

It would be neat to say Israeli growers now match the Dutch benchmark — but the honest picture is more mixed. Israeli companies have made real progress on the manufacturing standard: Panaxia became the first Israeli firm to earn EU-GMP certification (Newswire), and Cannbit–Tikun Olam followed with EU-GMP certification enabling export to Germany (PR Newswire). That certification is meaningful, and it lets Israeli product into Europe's pharmacy channel.

But EU-GMP certifies how a facility manufactures — it is not the same as the genetic standardisation Bedrocan is built on. Bedrocan's distinguishing feat is a small set of fixed, genetically identical chemovars that deliver the same cannabinoid-and-terpene fingerprint batch after batch, year after year. Israel's market, by contrast, has long run on a wide and shifting roster of cultivars and has leaned heavily on imports — to the point that Israel became the world's largest importer of medical cannabis flower. The country has world-class cannabinoid science and a growing GMP manufacturing base, but the specific discipline Bedrocan pioneered — true single-genotype, pharmaceutical-grade reproducibility — is something the Israeli industry is still building toward rather than something it has clearly matched. That gap is precisely where the opportunity lies for a serious Israeli producer.

Why it matters for Israel's story

It is tempting, on an Israel-focused site, to tell the cannabis story as a purely Israeli achievement. The honest version is a partnership of ideas. Israel contributed the foundational science; the Netherlands, through Bedrocan and the OMC, contributed the proof that the plant could be standardised and manufactured to pharmaceutical standards. Israel's modern industry — its GMP-certified producers, its export ambitions, its clinical trials — stands on both. Understanding Bedrocan is understanding the manufacturing half of how cannabis became medicine.

For the science side of that story, see Israel's cannabis research legacy and our profile of Raphael Mechoulam; for how the standards Bedrocan pioneered were written into Israeli law, see IMC-GAP and IMC-GMP explained.